These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15827690)

  • 1. Combined-modality treatment and organ preservation in bladder cancer. Do molecular markers predict outcome?
    Weiss C; Rödel F; Wolf I; Papadopoulos T; Engehausen DG; Schrott KM; Sauer R; Rödel C
    Strahlenther Onkol; 2005 Apr; 181(4):213-22. PubMed ID: 15827690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment proliferation and local control in bladder cancer after radiotherapy with or without concurrent chemotherapy.
    Weiss C; Rödel F; Ott O; Engehausen DG; Papadopoulos T; Sauer R; Rödel C
    Strahlenther Onkol; 2007 Oct; 183(10):552-6. PubMed ID: 17896086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
    Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
    Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organ-sparing treatment in muscle-invasive bladder cancer.
    Dunst J; Diestelhorst A; Kühn R; Müller AC; Scholz HJ; Fornara P
    Strahlenther Onkol; 2005 Oct; 181(10):632-7. PubMed ID: 16220401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation.
    Rödel C; Grabenbauer GG; Rödel F; Birkenhake S; Kühn R; Martus P; Zörcher T; Fürsich D; Papadopoulos T; Dunst J; Schrott KM; Sauer R
    Int J Radiat Oncol Biol Phys; 2000 Mar; 46(5):1213-21. PubMed ID: 10725634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience.
    Perdonà S; Autorino R; Damiano R; De Sio M; Morrica B; Gallo L; Silvestro G; Farella A; De Placido S; Di Lorenzo G
    Cancer; 2008 Jan; 112(1):75-83. PubMed ID: 18008364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer.
    Burcombe R; Wilson GD; Dowsett M; Khan I; Richman PI; Daley F; Detre S; Makris A
    Breast Cancer Res; 2006; 8(3):R31. PubMed ID: 16790076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy.
    Weiss C; von Römer F; Capalbo G; Ott OJ; Wittlinger M; Krause SF; Sauer R; Rödel C; Rödel F
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1455-60. PubMed ID: 19231102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer.
    Margel D; Tal R; Baniel J
    J Urol; 2007 Dec; 178(6):2297-300; discussion 2300-1. PubMed ID: 17936837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
    Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
    J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy.
    Lavertu P; Adelstein DJ; Myles J; Secic M
    Laryngoscope; 2001 Nov; 111(11 Pt 1):1878-92. PubMed ID: 11801963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
    Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
    J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer.
    Müller AC; Diestelhorst A; Kuhnt T; Kühn R; Fornara P; Scholz HJ; Dunst J; Zietman AL
    Strahlenther Onkol; 2007 Apr; 183(4):177-83. PubMed ID: 17406798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer.
    Tran E; Souhami L; Tanguay S; Rajan R
    Am J Clin Oncol; 2009 Aug; 32(4):333-7. PubMed ID: 19381080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia.
    Wittlinger M; Rödel CM; Weiss C; Krause SF; Kühn R; Fietkau R; Sauer R; Ott OJ
    Radiother Oncol; 2009 Nov; 93(2):358-63. PubMed ID: 19837472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
    Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome of chemoradiotherapy for T1G3 bladder cancer.
    Inoue M; Ishioka J; Fukuda H; Kageyama Y; Saito Y; Higashi Y
    Int J Urol; 2008 Aug; 15(8):747-50. PubMed ID: 18786198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor proliferation, p53 expression, and apoptosis in laryngeal carcinoma: relation to the results of radiotherapy.
    Lera J; Lara PC; Perez S; Cabrera JL; Santana C
    Cancer; 1998 Dec; 83(12):2493-501. PubMed ID: 9874454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
    Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy.
    Weiss C; Wittlinger M; Engehausen DG; Krause FS; Ott OJ; Dunst J; Sauer R; Rödel C
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1502-6. PubMed ID: 17935905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.